Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 3

Sponsor Class

OTHER 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 246Lymphoma 127Leukemia, Myeloid, Acute 103Lymphoma, Non-Hodgkin 98Precursor Cell Lymphoblastic Leukemia-Lymphoma 93Neoplasms, Plasma Cell 91Myelodysplastic Syndromes 90Leukemia 79Hodgkin Disease 78Lymphoma, Large B-Cell, Diffuse 66Leukemia, Lymphocytic, Chronic, B-Cell 65Lymphoma, Mantle-Cell 59Lymphoma, Follicular 57Neuroblastoma 44Burkitt Lymphoma 44Lymphoma, Large-Cell, Immunoblastic 40Lymphoma, B-Cell, Marginal Zone 37Recurrence 34Myeloproliferative Disorders 32Hematologic Neoplasms 31Leukemia, Myelogenous, Chronic, BCR-ABL Positive 30Immunoglobulin Light-chain Amyloidosis 29Leukemia, Myeloid, Accelerated Phase 25Leukemia, Myeloid, Chronic-Phase 24Congenital Abnormalities 24Leukemia, Myelomonocytic, Chronic 23Graft vs Host Disease 23Dendritic Cell Sarcoma, Interdigitating 21Waldenstrom Macroglobulinemia 20Anemia, Refractory, with Excess of Blasts 20

Interventions

Magnetic Resonance Spectroscopy 6Dexamethasone 6Cyclophosphamide 6Blood Specimen Collection 6Prednisone 5Positron Emission Tomography Computed Tomography 4Mammography 4Lenalidomide 4Colonoscopy 4pembrolizumab 3Tomography, X-Ray Computed 3Surveys and Questionnaires 3Melphalan 3Exercise 3Biopsy 32-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3weifuchun 2obinutuzumab 2fluciclovine F-18 2daratumumab 2carfilzomib 2Preoperative Exercise 2Positron-Emission Tomography 2Methods 2Magnetic Resonance Imaging 2Injections 2Gemcitabine 2Educational Status 2Doxorubicin 2Cytarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Disease × Melphalan × Clear all
NCT01093196 2024-11-07

Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients

Fondazione EMN Italy Onlus

Phase 3 Completed
660 enrolled
Plasma cell

Disease, Multiple Myeloma

NCT01190787 2024-01-23

Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone

European Myeloma Network B.V.

Phase 2 Completed
150 enrolled
Plasma cell

Disease, Multiple Myeloma

NCT01160107 2023-06-29

RP_MPR

Fondazione EMN Italy Onlus

Phase 2 Completed
46 enrolled
Plasma cell

Disease, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡